Literature DB >> 35146529

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.

Tanja Batinac, Nika Hlača, Luka Simetić, Frane Valković, Sandra Peternel1, Larisa Prpić-Massari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35146529      PMCID： PMC9558335          DOI： 10.2340/actadv.v102.1433

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  15 in total

Review 1.  Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.

Authors:  Kristy Kummerow Broman; Lesly A Dossett; James Sun; Zeynep Eroglu; Jonathan S Zager
Journal:  Expert Opin Drug Saf       Date:  2019-04-24       Impact factor: 4.250

Review 2.  Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.

Authors:  Aine O'reilly; James Larkin
Journal:  Expert Rev Anticancer Ther       Date:  2017-06-19       Impact factor: 4.512

3.  Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.

Authors:  B Dréno; A Ribas; J Larkin; P A Ascierto; A Hauschild; L Thomas; J-J Grob; D O Koralek; I Rooney; J J Hsu; E F McKenna; G A McArthur
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

4.  Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?

Authors:  A Gey; B Milpied; C Dutriaux; C Mateus; C Robert; G Perro; A Taieb; K Ezzedine; T Jouary
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-08-29       Impact factor: 6.166

5.  Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.

Authors:  Marie Lamiaux; Camille Scalbert; Pauline Lepesant; Eve Desmedt; Carole Templier; Véronique Dziwniel; Delphine Staumont-Sallé; Laurent Mortier
Journal:  Melanoma Res       Date:  2018-10       Impact factor: 3.599

6.  Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Authors:  Karim R Saab; Meghan J Mooradian; Daniel Y Wang; Jeewon Chon; Cathy Y Xia; Angelica Bialczak; Kelly T Abbate; Alexander M Menzies; Douglas B Johnson; Ryan J Sullivan; Alexander N Shoushtari
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

7.  Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.

Authors:  Sanja Poduje; Jasmina M Brozić; Ivana Prkačin; Marija Delaš Aždajić; Andy Goren
Journal:  Dermatol Ther       Date:  2019-12-11       Impact factor: 2.851

Review 8.  Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.

Authors:  Lucie Heinzerling; Thomas K Eigentler; Michael Fluck; Jessica C Hassel; Daniela Heller-Schenck; Jan Leipe; Matthias Pauschinger; Arndt Vogel; Lisa Zimmer; Ralf Gutzmer
Journal:  ESMO Open       Date:  2019-05-23

9.  Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.

Authors:  Ryo Sato; Kosuke Imamura; Shinya Sakata; Tokunori Ikeda; Yuko Horio; Shinji Iyama; Kimitaka Akaike; Shohei Hamada; Takayuki Jodai; Kei Nakashima; Shiho Ishizuka; Nahoko Sato; Koichi Saruwatari; Sho Saeki; Yusuke Tomita; Takuro Sakagami
Journal:  J Clin Med       Date:  2019-05-29       Impact factor: 4.241

10.  Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).

Authors:  I Torres-Navarro; B de Unamuno-Bustos; R Botella-Estrada
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-30       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.